The following surface antigens were selected for analysis: for myeloid tumors: MV-4-11, Thp-1, HL-60—CD11b, CD14, K562 and KG-1—CD34, and CD38; for lymphoid neoplasms: Raji, Daudi, U2932—CD19, CD20, Jurkat—CD4, CD8. This evidence concerns the gene CD8A and lymphoid neoplasm.